Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52834
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBongetti E.K.-
dc.contributor.authorWolfe R.-
dc.contributor.authorWetmore J.B.-
dc.contributor.authorMurray A.M.-
dc.contributor.authorWoods R.L.-
dc.contributor.authorFravel M.A.-
dc.contributor.authorNelson M.-
dc.contributor.authorStocks N.-
dc.contributor.authorOrchard S.G.-
dc.contributor.authorPolkinghorne K.-
dc.date.accessioned2025-01-06T02:50:46Z-
dc.date.available2025-01-06T02:50:46Z-
dc.date.copyright2024-
dc.date.issued2024-11-13en
dc.identifier.citationJournal of the American Society of Nephrology. Conference: Kidney Week 2024. San Diego, CA United States. 35(pp 415), 2024. Date of Publication: 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/52834-
dc.description.abstractBackground: A recalibrated version of CKD-EPI2009, without a race coefficient, was released in 2021 (CKD-EPI2021). This updated equation, implemented in the US, can result in the reclassification of chronic kidney disease (CKD) stage in a significant proportion of individuals. The aim of this study was to investigate the clinical impact of transitioning from the 2009 CKD-EPI (CKD-EPI2009) to the 2021 CKD-EPI (CKD-EPI2021) estimated glomerular filtration rate (eGFR) equation in generally healthy older Australians. Method(s): This was a prospective cohort study using data from 16,244 Australian community-dwelling adults aged >=70 years, in the ASPirin in Reducing events in the Elderly (ASPREE) study cohort. Baseline characteristics and long-term health outcomes were compared in participants who were reclassified to a different chronic kidney disease (CKD) stage with CKD-EPI2021 versus those with unchanged classification. Result(s): With CKD-EPI2021, baseline eGFR increased by a median of 3.8 mL/min/ 1.73m2 (interquartile range [IQR] 3.3, 4.4) resulting in the reclassification of 3,106 (20%) participants to a less advanced CKD stage and the reduction in the prevalence of CKD from 17% to 12%. Over a median follow-up period of 6.5 years (IQR 5.4, 7.9), there was no difference in disability-free survival (HR: 0.94, 95%CI:0.84-1.05), mortality (HR: 0.90, 95%CI:0.78-1.03), major cardiac events (HR: 0.94, 95%CI:0.79-1.13), or hospitalisations for heart failure (HR: 1.00, 95%CI:0.67-1.49) in reclassified, versus nonreclassified, participants. Conclusion(s): Implementing CKD-EPI2021 would raise eGFR by a median of nearly 4 ml/min/1.73m2, substantially reducing the proportion of older Australian adults classified as having CKD with no difference in long-term health outcomes among reclassified people. Transitioning to using the CKD-EPI2021 may result in a significant reduction in nephrology referrals in generally healthy, older adults.-
dc.relation.ispartofJournal of the American Society of Nephrology-
dc.subject.meshcardiovascular disease-
dc.subject.meshchronic kidney failure-
dc.titleImpact of the CKD-EPI 2021 equation on the classification of CKD in older Australian adults.-
dc.typeConference Abstract-
dc.identifier.affiliationNephrology-
dc.description.conferencenameKidney Week 2024-
dc.description.conferencelocationSan Diego, CA, United States-
dc.type.studyortrialObservational study (cohort, case-control, cross sectional, or survey)-
local.date.conferencestart2024-10-23-
dc.identifier.institution(Bongetti, Polkinghorne) Monash University, Department of Medicine, Clayton, VIC, Australia-
dc.identifier.institution(Bongetti, Polkinghorne) Department of Nephrology, Monash Health, Melbourne, VIC, Australia-
dc.identifier.institution(Wolfe, Woods, Orchard) Monash University, School of Public Health and Preventative Medicine, Melbourne, VIC, Australia-
dc.identifier.institution(Wetmore) Division of Nephrology, Hennepin Healthcare, Minneapolis, MN, United States-
dc.identifier.institution(Murray) Berman Center for Outcomes and Clinical Research and Department of Medicine, Hennepin Healthcare Research Institute, Department of Medicine, Geriatrics Division, Hennepin Healthcare, Minneapolis, MN, United States-
dc.identifier.institution(Fravel) Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Minneapolis, MN, United States-
dc.identifier.institution(Nelson) University of Tasmania, Menzies Institute for Medical Research, Hobart, TAS, Australia-
dc.identifier.institution(Stocks) Adelaide Medical School, Discipline of General Practice, Adelaide, SA, Australia-
local.date.conferenceend2024-10-27-
dc.identifier.affiliationmh(Bongetti, Polkinghorne) Department of Nephrology, Monash Health, Melbourne, VIC, Australia-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeConference Abstract-
crisitem.author.deptNephrology-
Appears in Collections:Conferences
Show simple item record

Page view(s)

24
checked on Mar 13, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.